Calamos Advisors LLC Ascendis Pharma A/S Transaction History
Calamos Advisors LLC
- $18.8 Billion
- Q3 2025
A detailed history of Calamos Advisors LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Calamos Advisors LLC holds 6,450 shares of ASND stock, worth $1.32 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,450Holding current value
$1.32 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ASND
# of Institutions
280Shares Held
60MCall Options Held
217KPut Options Held
73.3K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.11 Billion38.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.12 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.98MShares$1.02 Billion15.67% of portfolio
-
Janus Henderson Group PLC London, X04.43MShares$909 Million0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$874 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.5B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...